Tom Muller News
-
ING U.S. Inc., the New York-based unit of the largest Dutch financial-services company, raised $1.27 billion in its initial public offering, pricing an increased number of shares below the marketed range.
-
Akzo Nobel NV, the maker of specialty chemicals and Dulux paint, will look to make more cutbacks to offset a slump in Europe that’s left an existing 500 million-euro ($653 million) savings target outdated.
-
Saab Automobile , the Swedish carmaker that agreed last week to produce autos in China with Hawtai Motor Group , faces fresh uncertainty over its future after the plan failed win approval from authorities in the Asian nation.
-
SNS Reaal NV, a Dutch bank and insurer burdened with souring real estate loans, said it’s still in talks with private investors to bolster capital and that there’s no certainty a deal will be reached.
-
Julius Baer Group Ltd., Switzerland’s largest publicly traded private bank, is leading the race to acquire a stake in Bank Sarasin & Cie. AG held by Rabobank Groep, people familiar with the process said.
-
China, the world’s biggest steel producer, is exporting at the highest level in two years, exacerbating a global glut that may hurt competitors from ArcelorMittal to U.S. Steel Corp.
-
NXP Semiconductor NV is considering asking its owners for another stock sale this year to increase the number of freely traded shares and meet demand from shareholders aiming to invest in the Dutch chipmaker.
-
Akzo Nobel NV , the world’s biggest paint maker, will examine all options for its U.S. Glidden brand once an overhaul to improve margins is completed, according to Chief Executive Officer Hans Wijers .
-
Saab Automobile, the 64-year-old Swedish carmaker that halted production in June, applied for court protection from creditors in a bid to raise money to restart operations and avoid a bankruptcy petition by unions.
-
Johnson & Johnson said it will buy the rest of vaccine maker Crucell NV it doesn’t already own for $2.3 billion, expanding in flu shots to bolster sales after two former top-selling drugs lost patent protection.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page